We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,303 hedge funds and large institutions have $57.6B invested in Bristol-Myers Squibb in 2014 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 466 increasing their positions, 535 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.58% more ownership

Funds ownership: 70.98%71.56% (+0.58%)

2% less funds holding

Funds holding: 1,3291,303 (-26)

6% less capital invested

Capital invested by funds: $61.1B → $57.6B (-$3.49B)

13% less repeat investments, than reductions

Existing positions increased: 466 | Existing positions reduced: 535

21% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 84

25% less call options, than puts

Call options by funds: $538M | Put options by funds: $720M

35% less funds holding in top 10

Funds holding in top 10: 5737 (-20)

Holders
1,303
Holders Change
-26
Holders Change %
-1.96%
% of All Funds
37.43%
Holding in Top 10
37
Holding in Top 10 Change
-20
Holding in Top 10 Change %
-35.09%
% of All Funds
1.06%
New
66
Increased
466
Reduced
535
Closed
84
Calls
$538M
Puts
$720M
Net Calls
-$181M
Net Calls Change
-$297M
Name Holding Trade Value Shares
Change
Change in
Stake
HPC
401
HM Payson & Co
Maine
$4.68M +$13.8K +280 +0.3%
SIC
402
Salem Investment Counselors
North Carolina
$4.67M -$8.38K -170 -0.2%
First Trust Advisors
403
First Trust Advisors
Illinois
$4.64M -$7.62M -154,656 -62%
LMGAM
404
Liberty Mutual Group Asset Management
Massachusetts
$4.62M +$249K +5,061 +6%
FBT
405
First Bankers Trust
Kentucky
$4.6M +$138K +2,810 +3%
NRS
406
Neville Rodie & Shaw
New York
$4.59M +$365K +7,398 +8%
SCM
407
Stux Capital Management
New York
$4.55M -$784K -15,900 -14%
BCMU
408
BlueCrest Capital Management (UK)
Guernsey
$4.53M +$4.6M +93,407 New
PWLP
409
Prio Wealth Limited Partnership
Massachusetts
$4.51M -$170K -3,451 -4%
TCMG
410
TSP Capital Management Group
New Jersey
$4.44M +$4.51M +91,565 New
PAG
411
Private Advisor Group
New Jersey
$4.41M +$204K +4,134 +5%
RJFSA
412
Raymond James Financial Services Advisors
Florida
$4.4M +$1.01M +20,542 +29%
LPC
413
Loeb Partners Corp
New York
$4.35M
GAM
414
Gotham Asset Management
New York
$4.33M +$4.4M +89,363 New
AA
415
Apriem Advisors
California
$4.33M +$95K +1,927 +2%
PAM
416
Paradigm Asset Management
New York
$4.32M +$237K +4,800 +6%
WSCM
417
Wellington Shields Capital Management
New York
$4.3M -$29.4K -596 -0.7%
OCM
418
Orleans Capital Management
Louisiana
$4.29M +$56.2K +1,140 +1%
TNBTD
419
Trustmark National Bank Trust Department
Mississippi
$4.22M -$36K -731 -0.8%
Westfield Capital Management
420
Westfield Capital Management
Massachusetts
$4.16M -$172M -3,488,354 -98%
AAMU
421
Amundi Asset Management US
Massachusetts
$4.16M +$39.4K +800 +0.9%
DC
422
Davenport & Co
Virginia
$4.15M -$428K -8,680 -9%
RPAM
423
Rhenman & Partners Asset Management
Sweden
$4.12M -$89.4K -1,815 -2%
BOH
424
Bank of Hawaii
Hawaii
$4.06M -$414K -8,402 -9%
BFA
425
Bragg Financial Advisors
North Carolina
$4.05M -$17.9K -363 -0.4%

BMY Hedge Fund Activity: Q2 2014 in Review

1,303 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2014, worth a combined $57.6B — down 5.7% from $61.1B a quarter earlier.

Sellers outnumbered buyers: 84 funds closed out of BMY and 66 opened new positions — a net loss of 18 holders — while 535 trimmed existing stakes and 466 added.

The largest buyer was Wellington Management Group, adding an estimated $1.52B. The largest seller was Fidelity Investments, cutting an estimated $613M.

  • 1,303 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2014, down from 1,329 in Q1 2014.
  • Funds reported $57.6B of Bristol-Myers Squibb stock for Q2 2014, down 5.7% quarter-over-quarter.
  • 66 funds opened new Bristol-Myers Squibb positions in Q2 2014 and 84 closed out, a net change of -18 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2014 was Wellington Management Group, an estimated $1.52B added.
  • The largest Bristol-Myers Squibb seller in Q2 2014 was Fidelity Investments, an estimated $613M sold.

Based on aggregated 13F filings for Q2 2014.